A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

ClinicalTrials.gov ID: NCT01304524

Public ClinicalTrials.gov record NCT01304524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.

Study identification

NCT ID: NCT01304524
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Inovio Pharmaceuticals; Industry
Enrollment: 167 participants

Conditions and interventions

Conditions

Cervical Intraepithelial Neoplasia

Interventions

VGX 3100 Biological
Placebo Biological
CELLECTRA™-5P Device

Biological · Device

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2011
Primary completion: Apr 30, 2014
Completion: Mar 31, 2015
Last update posted: Sep 6, 2018

2011 – 2015

United States locations

U.S. sites: 27
U.S. states: 17
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85015	—
Not listed	Tucson	Arizona	85721	—
Not listed	Colton	California	92324	—
Not listed	La Mesa	California	91942	—
Not listed	Los Angeles	California	90036	—
Not listed	Lakewood	Colorado	80228	—
Not listed	Boynton Beach	Florida	33472	—
Not listed	Fort Lauderdale	Florida	33316	—
Not listed	Sarasota	Florida	34231	—
Not listed	Baltimore	Maryland	21205	—
Not listed	Saginaw	Michigan	48604	—
Not listed	Missoula	Montana	59808	—
Not listed	Port Jefferson	New York	11777	—
Not listed	The Bronx	New York	10467	—
Not listed	Raleigh	North Carolina	27607	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Columbus	Ohio	43231	—
Not listed	Oklahoma City	Oklahoma	73117	—
Not listed	Eugene	Oregon	97401	—
Not listed	Philadelphia	Pennsylvania	19122	—
Not listed	Myrtle Beach	South Carolina	29572	—
Not listed	Murray	Utah	84107	—
Not listed	Pleasant Grove	Utah	84062	—
Not listed	Sandy City	Utah	84070	—
Not listed	Richmond	Virginia	23233	—
Not listed	Renton	Washington	98055	—
Not listed	Spokane	Washington	99207	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01304524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 6, 2018 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01304524 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →